BioNTech SE
$204.8M 179 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. reported $199,919,045.16 across General Payments, Research, and Ownership to 172,058 physicians and teaching hospitals across 186,599 transactions.
- $199.9M
- All-tracks total
- 186,599
- Transactions
- 172,058
- Recipients
- +$17.3M
- General Payments vs PY2023
Takeda Pharmaceuticals U.S.A., Inc. reported $199,919,045.16 across all CMS Open Payments tracks (General + Research + Ownership) to 172,058 physicians and teaching hospitals in Program Year 2024 - ranking #15 of 1,925 reporting manufacturers (1.4% of the all-tracks industry total); General Payments alone were $72,798,431.97, averaging $1.2K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer takeda-pharmaceuticals-u-s-a-inc Takeda Pharmaceuticals U.S.A., Inc.
$199.9M · #15/1,925 · 1.4% industry · PY2024
- TOT $199.9M
- RANK #15
- SHARE 1.4%
- TXN 186,599
- RCP 172,058
- CAT 9
- GEN $72.8M
- ΔGEN +$17.3M
- TOP1 37.4%
- PY 2024
Volume peers
Nearest volume peer: BioNTech SE ($204.8M)
Takeda Pharmaceuticals U.S.A., Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Takeda Pharmaceuticals U.S.A., Inc.'s CMS-reported General Payments increased by $17.3M (+31.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: TAKEDA PHARMACEUTICALS U.S.A., INC.PY2023: TAKEDA PHARMACEUTICALS U.S.A., INC.PY2024: Takeda Pharmaceuticals U.S.A., Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $55,483,057.02
- PY2024
- $72,798,431.97
What the Data Shows for Takeda Pharmaceuticals U.S.A., Inc.
Averaging $1.1K per transaction and $1.2K per recipient, Takeda Pharmaceuticals U.S.A., Inc.'s Program Year 2024 total comes to $199,919,045.16 across 186,599 transactions and 172,058 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #15 of 1,925 companies, a top-tier 1.4% share of all industry payments reported nationwide for the year.
"Royalty or License" leads the 9-category general-payment breakdown below at $44.5M (61.1% of General Payments, 27 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 9 types of general payments, Takeda Pharmaceuticals U.S.A., Inc.'s largest category was "Royalty or License" at $44.5M - 61.1% of General Payments.
Takeda Pharmaceuticals U.S.A., Inc. reports 9 general-payment categories - the top three are Royalty or License (61.1%), Consulting Fee (14.4%), and Compensation for Services Other Than Consulting (8.7%). The remaining 6 categories make up 15.8% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Takeda Pharmaceuticals U.S.A., Inc. files across 9 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Takeda Pharmaceuticals U.S.A., Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $44.5M | 27 | 61.1% |
| Consulting Fee | $10.5M | 4,087 | 14.4% |
| Compensation for Services Other Than Consulting | $6.3M | 985 | 8.7% |
| Space Rental or Facility Fees | $3.6M | 469 | 5.0% |
| Food and Beverage | $3.5M | 162,392 | 4.8% |
| Grant | $2.0M | 27 | 2.8% |
| Travel and Lodging | $1.1M | 2,754 | 1.6% |
| Education | $654.4K | 1,310 | 0.9% |
| Charitable Contribution | $499.3K | 7 | 0.7% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $44,946,140.80 (61.7%) of $72,798,431.97 in this company's General Payments records across 52,038 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Takeda Pharmaceuticals U.S.A., Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Massachusetts General Hospital
$27,230,462.12 across 6 reported transactions
- 2
Childrens Hospital Corporation
$10,099,059.07 across 15 reported transactions
- 3
Univ of Mi Hospitals & Hlth Ctrs
$4,680,763.63 across 18 reported transactions
- 4
Emory University Hospital
$1,675,055.98 across 8 reported transactions
- 5
Cleveland Clinic Hospital
$1,260,800.00 across 32 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Takeda Pharmaceuticals U.S.A., Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Takeda Pharmaceuticals U.S.A., Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Takeda Pharmaceuticals U.S.A., Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Medtronic, Inc.
$189.9M 342,681 recipients
Compare payment profiles
GlaxoSmithKline, LLC.
$242.1M 341,439 recipients
Compare payment profiles
Boehringer Ingelheim Pharmaceuticals, Inc.
$148.9M 216,716 recipients
Compare payment profiles
E.R. Squibb & Sons, L.L.C.
$251.5M 236,558 recipients
Compare payment profiles
Stryker Corporation
$141.0M 168,381 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.